

U. PORTO

FMUP FACULDADE DE MEDICINA
UNIVERSIDADE DO PORTO

MESTRADO INTEGRADO EM MEDICINA

2015/2016

Beatriz Joana Bettencourt Silva
Nutritional Profile and Multiple Sclerosis
in a Cohort of Portuguese Patients

março, 2016

FMUP

Beatriz Joana Bettencourt Silva
Nutritional Profile and Multiple Sclerosis
in a Cohort of Portuguese Patients

Mestrado Integrado em Medicina

Área: Neurociências Clínicas e Saúde Mental

Tipologia: Dissertação

Trabalho efetuado sob a Orientação de:

Doutora Joana Guimarães

E sob a Coorientação de:

Doutora Flora Correia

Trabalho organizado de acordo com as normas da revista:

Multiple Sclerosis and Related Disorders

março, 2016

FMUP

Eu, Beatriz Joana Bettencourt Silva, abaixo assinado, nº mecanográfico 201002453, estudante do 6º ano do Ciclo de Estudos Integrado em Medicina, na Faculdade de Medicina da Universidade do Porto, declaro ter atuado com absoluta integridade na elaboração deste projeto de opção.

Neste sentido, confirmo que **NÃO** incorri em plágio (ato pelo qual um indivíduo, mesmo por omissão, assume a autoria de um determinado trabalho intelectual, ou partes dele). Mais declaro que todas as frases que retirei de trabalhos anteriores pertencentes a outros autores, foram referenciadas, ou redigidas com novas palavras, tendo colocado, neste caso, a citação da fonte bibliográfica.

Faculdade de Medicina da Universidade do Porto, 23/03/2016

Assinatura conforme cartão de identificação:

Beatriz Joana Bettencourt Silva

NOME

Beatriz Joana Bettencourt Silva

NÚMERO DE ESTUDANTE

201002453

DATA DE CONCLUSÃO

DESIGNAÇÃO DA ÁREA DO PROJECTO

Neurociências Clínicas e Saúde Mental

TÍTULO DISSERTAÇÃO/MONOGRAFIA (riscar o que não interessa)

Nutritional Profile and Multiple Sclerosis in a Cohort of Portuguese Patients

ORIENTADOR

Doutora Joana Guimarães

COORIENTADOR (se aplicável)

Doutora Flora Correia

ASSINALE APENAS UMA DAS OPÇÕES:

É AUTORIZADA A REPRODUÇÃO INTEGRAL DESTES TRABALHOS APENAS PARA EFEITOS DE INVESTIGAÇÃO, MEDIANTE DECLARAÇÃO ESCRITA DO INTERESSADO, QUE A TAL SE COMPROMETE.	☐
É AUTORIZADA A REPRODUÇÃO PARCIAL DESTES TRABALHOS (INDICAR, CASO TAL SEJA NECESSÁRIO, Nº MÁXIMO DE PÁGINAS, ILUSTRAÇÕES, GRÁFICOS, ETC.) APENAS PARA EFEITOS DE INVESTIGAÇÃO, MEDIANTE DECLARAÇÃO ESCRITA DO INTERESSADO, QUE A TAL SE COMPROMETE.	☐
DE ACORDO COM A LEGISLAÇÃO EM VIGOR, (INDICAR, CASO TAL SEJA NECESSÁRIO, Nº MÁXIMO DE PÁGINAS, ILUSTRAÇÕES, GRÁFICOS, ETC.) NÃO É PERMITIDA A REPRODUÇÃO DE QUALQUER PARTE DESTES TRABALHOS.	☒

Faculdade de Medicina da Universidade do Porto, 23 / 03 / 2016

Assinatura conforme cartão de identificação:

Beatriz Joana Bettencourt Silva

Dedicatória

Aos meus pais, que são a base da minha formação pessoal e académica;

À Rita, a minha maior conselheira, por sempre me apoiar e fazer-me sentir em casa;

Ao David, pelo suporte e disponibilidade incondicionais.

Nutritional Profile and Multiple Sclerosis in a Cohort of Portuguese Patients

Beatriz Silva ^{a,*}, Flora Correia, PhD ^b, Rui Poínhos, PhD ^b, Joana Guimarães, MD, PhD ^c

^a *Sixth year student of the Integrated Master Degree in Medicine, Faculty of Medicine, University of Porto, Porto, Portugal*

^b *Faculty of Nutrition, Food Science, University of Porto, Porto, Portugal*

^c *Department of Neurology, Centro Hospitalar São João, E.P.E., Porto, Portugal*

* Corresponding author:

Department of Neurology, Centro Hospitalar São João, E.P.E.

Alameda Professor Hernâni Monteiro, 4200-319, Porto, Portugal

Tel.: +351911160120

E-mail address: beatrizbettsilva@gmail.com

Abstract

Background: The research on health behaviours of multiple sclerosis (MS) patients has been intensified in the last years. The proposal is to identify and intervene on modifiable factors, such as physical activity, weight control and dietary habits to delay disability and improve overall quality of life.

Objective: This study aims to evaluate associations of dietary habits, body mass index (BMI) and body composition with the Expanded Disability Status Scale (EDSS).

Material and methods: We investigated a cohort of 37 Portuguese adults with relapsing MS onset. They performed a nutritional evaluation, including food intake frequencies, height, weight and body composition [percentages of total body water (%TBW), soft lean mass (%SLM), fat body mass (%FBM) and phase angle], and were asked about their smoking status and physical activity. We also assessed demographic information and MS characteristics, including EDSS.

Results: Seventeen (45.9%) patients were overweight or obese, but there was no statistically significant correlation between body mass index (BMI) and EDSS. Patients with higher EDSS had significantly lower phase angle ($p=0.003$), %TBW ($p=0.024$) and %SLM ($p=0.024$), as well as greater %FBM ($p=0.025$). Weekly intake of alcoholic beverages had a negative correlation with EDSS ($p=0.006$). There was also a significant negative correlation between EDSS and physical activity level ($p=0.002$).

Conclusions: We hypothesize that neurological disability leads to deleterious changes in body composition of MS patients. The %FBM seems to be a better marker of the risk of comorbid-health conditions than BMI in MS patients and phase angle appears to have a considerable correlation with disability progression. We cannot conclude about the effective impact of dietary habits on MS course.

Keywords:

Multiple sclerosis

EDSS

Nutrition

Body mass index

Body composition

Phase angle

1. Introduction

Multiple Sclerosis (MS) is a progressive autoimmune-mediated disease but its cause still unknown. Previous research suggests that MS has a multifactorial nature, with involvement of genetic, immunological and environmental factors in a complex aetiology [1-4]. The environmental risk factors most associated with MS are low vitamin D status, prior infection with Epstein-Barr virus and tobacco smoking [2,3,5-8]. Tobacco smoking also seems to have a negative impact on MS progression [9,10].

Although there are disease-modifying therapies that slow disease progression and prevent some symptoms, MS therapeutics remain limited and the disease leads to a progressive disability and a reduced quality of life [2,6,11]. In the past years, the investigation on health behaviours of MS patients has been intensified trying to identify and intervene on modifiable factors that could delay disability and improve the overall quality of life.

Physical activity probably generates important outcomes in MS patients, with both physical and mental improvements. Animal studies also suggest neuroprotective benefits. Unfortunately, a disease-modifying effect of physical activity in MS patients cannot be surely affirmed given the limited strength of evidence and the heterogeneous findings [12-14].

Studies have shown that a large body size during adolescence and young adulthood was associated with an increased risk of MS [7,15,16]. The pathophysiological mechanisms suggested seem to be complex, including change on adipokines' secretion and higher prevalence of vitamin D deficiency among obese subjects. Data from experimental models suggested a negative impact of obesity in MS course and prognosis, but clinical investigation remain limited [17]. Some studies showed that prevalence of overweight or obesity is around 50% in MS patients with established diagnosis or at MS onset [18-21]. Interestingly, patients with significant disability are likely to have higher proportion of underweight [19,22,23].

The prevalence of fatigue and impaired muscle and movement functions is very high among MS patients [11] and there is no doubt that physical activity decreases steadily with disability progression [14,18,19]. Along with the possible abnormalities in skeletal muscle [24], these patients seems to have an increased fat mass and a reduced lean mass in the lower limbs [24,25]. However, studies reporting body composition of MS patients are limited and no association has been established with their disability progression.

Currently, there is no direct evidence indicating a crucial role of nutrition in MS aetiology or progression. In the last years, the increasing amount of research shows the crescent interest in dietary habits as an important target in these patients [1,2].

Omega-3 long-chain polyunsaturated fatty acids (n-3 PUFA) found in fish may be beneficial due to their neuroprotective, anti-inflammatory and immunomodulatory effects [1-3,6,22,26]. Some authors suggested that n-3 PUFA enriched diet is helpful as a complementary

Abbreviations: CHSJ, Centro Hospitalar São João; EDSS, Expanded Disability Status Scale; FBM, fat body mass; IPAQ, International Physical Activity Questionnaire; MRI, magnetic resonance imaging; MS, multiple sclerosis; n-3 PUFA, omega-3 long-chain polyunsaturated fatty acids; NHANES III, third National Health and Nutrition Examination Survey; PA, phase angle; SLM, soft lean mass; TBW, total body water; %FBM, percentage of fat body mass; %SLM, percentage of soft lean mass; %TBW, percentage of total body water.

treatment to MS. This idea is supported by experimental studies, but clinical trials are inconclusive [1,6]. Other bioactive molecules frequently studied are polyphenols (found in vegetables and fruit) and carotenoids (mainly found in vegetables). Since oxidative stress is considered one of the most critical processes implicated in demyelination and axonal damage, these anti-oxidative substances could have a role in disease modulation. One of the most important polyphenols is resveratrol, that is found in nuts, some fruits and wine, which seems to have neuroprotective effects [2,3].

It has been suggested a promising effect of specific consumptions, such as caffeine [26,27] or alcohol [7,26,28] in MS progression. On the other hand, some eating habits seems to have a negative association with MS, including high intake of animal fat, smoked meat products, sugar, sweets, sweetened beverages or cow milk [2,3,5].

Available data is still limited to make specific dietary recommendations for MS improvement and there are few studies on dietary intake habits and body composition of MS patients. In the present study, we aim to assess health behaviours in a cohort of Portuguese MS patients and analysed their association with MS status. Our primary goal is to evaluate the associations of dietary habits, body mass index (BMI) and body composition with the MS disability scale. We also intend to evaluate the impact of smoking status and physical activity.

2. Methods

2.1. Study Population and Data Collection

The study population included adult patients with MS diagnosis followed at the Neurology Department of Centro Hospitalar São João (CHSJ). MS diagnosis was established according to McDonald criteria [29]. At the time of their visit to neurology outpatient clinic between January and June of 2015, patients were asked to participate in the study and provided informed consent. After that, patients were guided to the nutrition unit of CHSJ to perform a nutritional evaluation and assess anthropometric and body composition measures. The nutritional evaluation was obtained through a face-to-face interview conducted by a nutritionist.

The following data was collected from each patient's interview: daily intake frequency of cow milk and/or yogurt, coffee, fruit, vegetables and weekly intake frequency of nuts (such as peanuts, almonds, pine nuts and walnuts), meat, fish and alcoholic beverages. We also asked the patients about their smoking status and classified them as never smoker, current smoker or former smoker. Physical activity was recorded using the short form of the International Physical Activity Questionnaire (IPAQ) and classified as low, moderate or high [30].

The anthropometric measures assessed were height (self-reported by each patient) and body weight (assessed with light clothing, without metal accessories nor shoes). We calculated their BMI by dividing weight (in kilograms) by height (in meters) squared and categorized it by World Health Organization classification: $<18.5 \text{ kg/m}^2$ is considered underweight, 18.5 to <25

kg/m² normal weight, 25 to <30 kg/m² overweight and ≥30 kg/m² obese. The body composition of each patient was obtained by the body composition analyser InBody720® (Direct Segmental Multi-frequency Bioelectrical Impedance Analysis Method) and the values of total body water (TBW), in litres, soft lean mass (SLM) and fat body mass (FBM), in kilograms, were extracted to our database. The percentages of TBW (%TBW), SLM (%SLM) and FBM (%FBM) were calculated by dividing each absolute value by total weight. One patient didn't fulfil this evaluation due to physical limitations. The phase angle (PA) was calculated directly from reactance and resistance. It represents a measure of cellular health and correlates with nutritional and functional status [31].

In medical records we assessed demographic information and MS characteristics, including year of diagnosis, relapsing or progressive disease onset, immunomodulatory drugs used, results of the last magnetic resonance imaging (MRI) scan (presence or absence of black holes and presence or absence of gadolinium-enhancing lesions) and neurological disability using the Expanded Disability Status Scale (EDSS) [32].

2.2. Statistical Analysis

Data were analysed using IBM® SPSS Statistics for Windows, version 23.0 (Armonk, N.Y., USA: IBM Corp.). Kolmogorov-Smirnov test was used to assess normality. As all cardinal variables were non-normal distributed, the analysis was based on non-parametric tests.

Descriptive statistics are presented as absolute (*n*) and relative (%) frequencies for categorical data or medians and percentiles 25th (P25) and 75th (P75) for quantitative data. Spearman's correlation coefficient (*r_s*) was used to measure the association between pair of quantitative variables and Mann-Whitney test was performed to compare mean ranks of two independent samples. Values of *p*<0.05 were considered statistically significant.

This study was approved by the ethics committee of CHSJ, Porto, Portugal.

3. Results

3.1. Study population characteristics

A total of 37 adult MS patients were included. All patients were white, most of them were women (81.1%), with a median age of 37.5 years and median time since MS diagnosis of 5 years. All patients had a relapsing disease onset, with median EDSS of 1 and only two patients had no immunomodulatory treatment. More than one-half (55.6%) of the patients had black holes and 7 (19.4%) patients had gadolinium-enhancing lesions on the last MRI scan. Additional information is showed in Table 1.

3.2. Smoking status and physical activity

About two-thirds (66.7%) of patients have never smoking and 7 (19.4%) patients were current smokers (Table 1). No significant association was found between smoking status and EDSS (Table 2). Less than one-third (28.6%) of patients reported low physical activity and 20 (57.1%) patients reported moderate physical activity (Table 1). A statistically significant negative correlation ($p=0.002$) was found between EDSS and physical activity level (Table 3).

3.3. BMI

Twenty (54.1%) patients were normal weight, 12 (32.4%) overweight and 5 (13.5%) obese (Table 1). There was no statistically significant correlation between EDSS and BMI (Table 3).

3.4. Body composition

The medians (P25; P75) of TBW, SLM, FBM and PA by sex are showed in Table 1. Patients with higher EDSS had significantly lower %TBW ($p=0.024$), %SLM ($p=0.024$) and PA ($p=0.003$), as well as greater %FBM ($p=0.025$) (Table 3).

3.5. Food intake frequencies

Only the frequency of alcoholic beverages intake had a statistically significant negative correlation with EDSS ($p=0.006$) (Table 3).

Table 1

Demographic and clinical characteristics of study population.

Sex [n (%)]	
Female	30 (81.1)
Male	7 (18.9)
Age - years [median (P25 ; P75)]	37.5 (27.7 ; 47.3)
Time since MS diagnosis - years [median (P25 ; P75)]	5 (1 ; 10)
Immunomodulatory treatment [n (%)]	
Interferon beta-1b	9 (24.2)
Interferon beta-1a	14 (37.8)
Glatiramer acetate	3 (8.1)
Fingolimod	2 (5.4)
Natalizumab	5 (13.5)
Fampridin	1 (2.7)
Teflunomide	1 (2.7)
No treatment	2 (5.4)
EDSS [median (P25 ; P75)]	1.0 (0.0 ; 2.5)
Last MRI scan [n (%)]	
Gadolinium-enhancing lesions	
Present	7 (19.4)
Absent	29 (80.6)
Black Holes	
Present	20 (55.6)
Absent	16 (44.4)
Smoking status [n (%)]	
Never	24 (66.7)
Current	7 (19.4)
Former	5 (13.9)
Physical activity [n (%)]	
Low	10 (28.6)
Moderate	20 (57.1)
High	5 (14.3)
BMI categorization [n (%)]	
Normal weight	20 (54.1)
Overweight	12 (32.4)
Obese	5 (13.5)
TBW - litres [median (P25 ; P75)]	
Female	30.3 (27.9 ; 32.1)
Male	42.8 (41.3 ; 43.5)
SLM - kilograms [median (P25 ; P75)]	
Female	38.8 (35.8 ; 42.3)
Male	55.0 (53.2 ; 55.9)
FBM - kilograms [median (P25 ; P75)]	
Female	22.3 (16.5 ; 29.0)
Male	10.8 (6.9 ; 21.1)
PA [median (P25 ; P75)]	
Female	5.1 (4.7 ; 5.6)
Male	6.1 (5.5 ; 6.7)

Table 2

Characterization of EDSS according to smoking status (Mann-Whitney test).

Variable	EDSS [median (P25 ; P75)]	<i>p</i>
Smoking status (<i>n</i> =36)		
Never	1.0 (0.0 ; 2.5)	0.693
Current or former	1.0 (1.0 ; 3.4)	

Table 3

Spearman's correlation coefficients (*rs*) between EDSS and physical activity, BMI, body composition parameters and food intake frequencies.

Variable	EDSS [<i>rs</i> (<i>p</i>)]
Physical activity (<i>n</i> =35)	-0.513 (0.002)
BMI (<i>n</i> =37)	0.271 (0.104)
%TBW (<i>n</i> =36)	- 0.376 (0.024)
%SLM (<i>n</i> =36)	- 0.376 (0.024)
%FBM (<i>n</i> =36)	0.373 (0.025)
PA (<i>n</i> =35)	- 0.488 (0.003)
Daily frequency intake:	
Cow milk and/or yogurt (<i>n</i> =37)	- 0.011 (0.947)
Coffee (<i>n</i> =37)	0.026 (0.877)
Fruit (<i>n</i> =37)	- 0.225 (0.181)
Vegetables (<i>n</i> =37)	- 0.019 (0.911)
Weekly frequency intake:	
Meat (<i>n</i> =35)	- 0.231 (0.182)
Fish (<i>n</i> =35)	- 0.111 (0.526)
Nuts (<i>n</i> =35)	- 0.100 (0.567)
Alcoholic beverages (<i>n</i> =36)	- 0.449 (0.006)

4. Discussion

This study is one of the few studies presenting an overview of dietary habits and body composition in MS patients, as well as their associations with EDSS. We have also complemented the evaluation of health behaviours assessing physical activity and smoking status.

Our sample presented a slightly less frequency of overweight and obesity among MS patients (45.9%) when compared to previous studies, which showed prevalence between 47.5% and 56.3% [18,19,21]. Although the considerable prevalence of overweight and obesity, a prospective study including 269 individuals with relapsing-remitting MS suggested that BMI had minimal impact on disability progression [21]. In agreement with those results, we found no significant association between BMI and EDSS. The association between BMI and MS disability status remains unclear. An unsolved question is whether the high prevalence of overweight/obesity in these patients develops independently or due to MS or its specific treatments. However, our results highlight the importance of weight status evaluation in these patients given the percentage of BMI values exceeding values recommended for health.

A study evaluating BMI and body composition in MS patients concluded that BMI threshold for obesity has a high specificity but underestimates true adiposity when compared to the percentage of body fat-defined obesity [33]. If we stratified our results of %FBM according to the values widely use as reference to define obesity (FBM $\geq$ 25% for men and $\geq$ 35% for women) [34], the proportion of patients classified as obese increase over 30% when compared to BMI classification (44.4% vs. 13.5%). These results may alert physicians to the importance of body composition evaluation as a marker of potential comorbidities' risk, such as cardiovascular disease, and reduced health-related quality of life even in patients with BMI $<$ 30 kg/m².

Previous research evaluating body composition found no significant differences between the %FBM of MS patients when they were compared with controls. There was no significant association between disability scales and components of body mass composition [25,35,36]. In contrast to those studies, we found a significant association between EDSS and %TBW, %SLM and %FBM. Patients with higher EDSS had significantly lower %TBW, lower %SLM and higher %FBM. These results suggest that neurological disability must lead to deleterious changes in body composition, increasing the risk of comorbid-health conditions.

Since we didn't have a control group, body composition parameters were compared with standardized values for sex and age groups described in population-based data from the third National Health and Nutrition Examination Survey (NHANES III) [37]. This comparative analysis intends to give us an estimate of how our sample approaches population standards. However, its interpretation may be limited because standard values proposed by NHANES III are not necessarily applicable to Portuguese population. Most of participants (75%) presented TBW (in litres) and FBM (in kilograms) within the 95% confidence intervals showed in NHANES III.

Interestingly, 29 participants (82.9%) have a PA below the 95% confidence interval showed in NHANES III. Individuals with chronic diseases frequently present a lower PA than healthy subjects due to the influence of parameters like infection or inflammation [31]. Therefore,

the lower PA in most of our patients may reflect the disease negative effect on this parameter. Previous studies reported a predictive effect of PA on prognosis of several diseases (mortality and disease progression) [31]. For example, a study conducted on patients with amyotrophic lateral sclerosis showed that lower values of PA were significantly associated with shorter six-month survival [38]. In our study, PA was significantly lower in participants with higher EDSS, bringing up the question of a possible relationship between PA and disability in MS patients.

We found a significant association between EDSS and the frequency of alcohol consumption. The impact of alcohol consumption in MS is controversial and the information about alcohol use among MS patients is limited. In our study, patients with lower EDSS reported a significantly higher frequency of alcoholic beverages intake. This finding is supported by a large study in relapsing onset MS patients that reported an inverse association between alcohol consumption and the risk of reaching EDSS 6 [26]. Furthermore, moderate consumption of alcoholic beverages seems to have a potential anti-inflammatory effect due to ethanol's properties on reducing pro-inflammatory cytokines synthesis or monocyte inflammatory responses [39]. Although we cannot exclude reverse causality, the association found by our group lead us to hypothesize a beneficial effect of alcoholic beverages consumption on neurological disability.

Although a previous reported association of a higher coffee and fish consumption with a lower progression rate in relapsing onset MS [26], our results did not show any significant association between daily intake of coffee or fish and EDSS.

Two large studies found a high prevalence of ever smoking among MS patients (over 17% current smokers and 29% to 38% former smokers) [9,19]. One of them suggested an adverse effect of smoking in MS progression [9]. In our sample, 7 patients (19.4%) were current smokers and 5 (13.9%) were former smokers. Although the relative frequency of current smokers has been higher comparatively to those studies, we found no significant association between smoking status and EDSS.

Regarding physical activity, a large study reported a predominant sedentary lifestyle among MS patients [19]. In contrast, 25 (71.4%) patients in our study reported moderate or vigorous physical activity. This proportion approaches the results of a survey study applied in 123 women with MS, most of them (85%) ambulatory patients [18]. Therefore, the exclusive inclusion of ambulatory patients in our study may explain the higher level of physical activity. A cross-sectional study had already suggest a positive effect of physical activity on reducing the risk of progression to EDSS 6 in relapsing onset MS [4]. In our study, patients with lower EDSS had a significantly higher physical activity level. We cannot conclude a beneficial effect of physical activity on delaying disability progression since the level of physical activity may be a reflection of functional status. Nevertheless, it is important to take physical activity in concern as a point of complementary intervention in MS patients.

Our study has some limitations. The interpretation of dietary intake results was limited due to the absence of quantitative evaluation. Data that was self-reported in face-to-face interviews may have some inaccuracy related to patient and interviewer subjectivity. Given the small sample size, multivariable adjustment for confounders such as sex, age, years since the

diagnosis and immunomodulatory treatment was not viable. In addition, there were some missing values and we cannot exclude a change in health behaviours of MS patients over time. The main strength of this study is the assessment of dietary intake and body composition in MS patients, since there are few studies reporting that. Moreover, after nutritional evaluation the participants had opportunity to receive counselling on healthy dietary habits and general recommendations for health.

5. Conclusion

Our findings enhance the importance of assessing body composition as part of MS patients' evaluation. We hypothesize that neurological disability leads to deleterious changes in body composition, namely increasing %FBM, which seems to be a better marker for risk of comorbid-health conditions than BMI in these patients. Furthermore, PA appears to have a considerable correlation with neurological disability. However, we cannot conclude that dietary habits have an effective impact on MS course. Large prospective studies are needed to infer causal relationships between specific dietary habits and MS outcomes, as well as to evaluate body composition changes during disease's progression. It is important to clarify how changes in life-style may play a beneficial role on quality of life and MS course.

Conflicts of interest

The authors declare no conflicts of interest.

Acknowledgements

Support for this study was provided by Cristina Arteiro, Mafalda Quelhas, Tiago Silva, Luís Silva, Alexandra Oliveira and Rita Simões, nutritionists from the Nutrition and Dietetics Unit of CHSJ. The authors are also grateful to Pedro Souteiro, MD, for the language review of this manuscript.

References

1. Payne, A., *Nutrition and diet in the clinical management of multiple sclerosis*. J Hum Nutr Diet, 2001. **14**(5): p. 349-57.
2. Riccio, P. and R. Rossano, *Nutrition facts in multiple sclerosis*. ASN Neuro, 2015. **7**(1).
3. von Geldern, G. and E.M. Mowry, *The influence of nutritional factors on the prognosis of multiple sclerosis*. Nat Rev Neurol, 2012. **8**(12): p. 678-89.
4. D'Hooghe M, B., et al., *Self-reported health promotion and disability progression in multiple sclerosis*. J Neurol Sci, 2013. **325**(1-2): p. 120-6.
5. Habek, M., I. Hojsak, and V.V. Brinar, *Nutrition in multiple sclerosis*. Clin Neurol Neurosurg, 2010. **112**(7): p. 616-20.
6. Schmitz, K., et al., *"Disease modifying nutricals" for multiple sclerosis*. Pharmacol Ther, 2015. **148**: p. 85-113.

7. Overs, S., et al., *Modifiable comorbidities and disability in multiple sclerosis*. Curr Neurol Neurosci Rep, 2012. **12**(5): p. 610-7.
8. Ponsonby, A.L., et al., *The physical anthropometry, lifestyle habits and blood pressure of people presenting with a first clinical demyelinating event compared to controls: the Ausimmune study*. Mult Scler, 2013. **19**(13): p. 1717-25.
9. Healy, B.C., et al., *Smoking and disease progression in multiple sclerosis*. Arch Neurol, 2009. **66**(7): p. 858-64.
10. Correale, J. and M.F. Farez, *Smoking worsens multiple sclerosis prognosis: two different pathways are involved*. J Neuroimmunol, 2015. **281**: p. 23-34.
11. Wynia, K., et al., *The impact of disabilities on quality of life in people with multiple sclerosis*. Mult Scler, 2008. **14**(7): p. 972-80.
12. Andreassen, A.K., E. Stenager, and U. Dalgas, *The effect of exercise therapy on fatigue in multiple sclerosis*. Mult Scler, 2011. **17**(9): p. 1041-54.
13. Dalgas, U. and E. Stenager, *Exercise and disease progression in multiple sclerosis: can exercise slow down the progression of multiple sclerosis?* Ther Adv Neurol Disord, 2012. **5**(2): p. 81-95.
14. Motl, R.W., *Lifestyle physical activity in persons with multiple sclerosis: the new kid on the MS block*. Mult Scler, 2014. **20**(8): p. 1025-1029.
15. Munger, K.L., T. Chitnis, and A. Ascherio, *Body size and risk of MS in two cohorts of US women*. Neurology, 2009. **73**(19): p. 1543-50.
16. Wesnes, K., et al., *Body size and the risk of multiple sclerosis in Norway and Italy: the EnvIMS study*. Mult Scler, 2015. **21**(4): p. 388-95.
17. Versini, M., et al., *Obesity in autoimmune diseases: not a passive bystander*. Autoimmun Rev, 2014. **13**(9): p. 981-1000.
18. Slawta, J.N., et al., *Health behaviors, body composition, and coronary heart disease risk in women with multiple sclerosis*. Arch Phys Med Rehabil, 2003. **84**(12): p. 1823-30.
19. Marrie, R., et al., *High frequency of adverse health behaviors in multiple sclerosis*. Mult Scler, 2009. **15**(1): p. 105-13.
20. Marrie, R.A., et al., *Association between comorbidity and clinical characteristics of MS*. Acta Neurol Scand, 2011. **124**(2): p. 135-41.
21. Pilutti, L.A., E. McAuley, and R.W. Motl, *Weight status and disability in multiple sclerosis: An examination of bi-directional associations over a 24-month period*. Mult Scler Relat Disord, 2012. **1**(3): p. 139-44.
22. Schwarz, S. and H. Leweling, *Multiple sclerosis and nutrition*. Mult Scler, 2005. **11**(1): p. 24-32.
23. Pinhas-Hamiel, O., et al., *Prevalence of overweight, obesity and metabolic syndrome components in multiple sclerosis patients with significant disability*. Eur J Neurol, 2015. **22**(9): p. 1275-9.
24. Wens, I., et al., *Multiple sclerosis affects skeletal muscle characteristics*. PLoS One, 2014. **9**(9): p. e108158.
25. Sioka, C., et al., *Body composition in ambulatory patients with multiple sclerosis*. J Clin Densitom, 2011. **14**(4): p. 465-70.
26. D'Hooghe M, B., et al., *Alcohol, coffee, fish, smoking and disease progression in multiple sclerosis*. Eur J Neurol, 2012. **19**(4): p. 616-24.
27. Horrigan, L.A., J.P. Kelly, and T.J. Connor, *Caffeine suppresses TNF-alpha production via activation of the cyclic AMP/protein kinase A pathway*. Int Immunopharmacol, 2004. **4**(10-11): p. 1409-17.
28. Hedstrom, A.K., et al., *Alcohol as a modifiable lifestyle factor affecting multiple sclerosis risk*. JAMA Neurol, 2014. **71**(3): p. 300-5.
29. Polman, C.H., et al., *Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria*. Ann Neurol, 2011. **69**(2): p. 292-302.
30. Craig, C.L., et al., *International physical activity questionnaire: 12-country reliability and validity*. Med Sci Sports Exerc, 2003. **35**(8): p. 1381-95.
31. Norman, K., et al., *Bioelectrical phase angle and impedance vector analysis--clinical relevance and applicability of impedance parameters*. Clin Nutr, 2012. **31**(6): p. 854-61.

32. Goldman, M.D., R.W. Motl, and R.A. Rudick, *Possible clinical outcome measures for clinical trials in patients with multiple sclerosis*. Ther Adv Neurol Disord, 2010. **3**(4): p. 229-39.
33. Pilutti, L.A. and R.W. Motl, *Body Mass Index Underestimates Adiposity in Persons With Multiple Sclerosis*. Arch Phys Med Rehabil, 2015.
34. Okorodudu, D.O., et al., *Diagnostic performance of body mass index to identify obesity as defined by body adiposity: a systematic review and meta-analysis*. Int J Obes (Lond), 2010. **34**(5): p. 791-9.
35. Ward, C.L., et al., *Body composition and physical function in women with multiple sclerosis*. J Rehabil Res Dev, 2013. **50**(8): p. 1139-47.
36. Lambert, C.P., R. Lee Archer, and W.J. Evans, *Body composition in ambulatory women with multiple sclerosis*. Arch Phys Med Rehabil, 2002. **83**(11): p. 1559-61.
37. Chumlea, W.C., et al., *Body composition estimates from NHANES III bioelectrical impedance data*. Int J Obes Relat Metab Disord, 2002. **26**(12): p. 1596-609.
38. Desport, J.C., et al., *Phase angle is a prognostic factor for survival in amyotrophic lateral sclerosis*. Amyotroph Lateral Scler, 2008. **9**(5): p. 273-8.
39. Imhof, A., et al., *Overall alcohol intake, beer, wine, and systemic markers of inflammation in western Europe: results from three MONICA samples (Augsburg, Glasgow, Lille)*. Eur Heart J, 2004. **25**(23): p. 2092-100.

Highlights

A high proportion of multiple sclerosis patients exceed body mass index and body composition values recommended for health.

Neurological disability seems to promote deleterious changes in body composition, namely increasing the percentage of fat body mass.

The percentage of fat body mass seems to be a better marker of the risk of comorbid-health conditions than body mass index in these patients.

Phase angle appears to have a considerable correlation with neurological disability.

Agradecimentos:

Em primeiro lugar, deixo o meu sincero agradecimento à Prof.^a Doutora Joana Guimarães e à Professora Doutora Flora Correia pela disponibilidade e pelo papel fundamental na idealização e realização deste trabalho, sempre com uma análise crítica e construtiva sobre o mesmo.


Em seguida, gostaria de agradecer à Dr.^a Cristina Arteiro, Mestre em Nutrição Clínica, Dr.^a Mafalda Quelhas, Dr. Tiago Silva, Dr. Luís Silva, Dr.^a Alexandra Oliveira e Dr.^a Rita Simões, nutricionistas da Unidade de Nutrição e Dietética do Centro Hospital São João (CHSJ) que colaboraram na avaliação nutricional dos participantes neste estudo.

Agradeço também ao Prof. Doutor Rui Poínhos, pelas orientações cruciais na análise estatística e pelo atencioso suporte na revisão dos métodos e resultados.

Finalmente, gostaria de agradecer ao Dr. Pedro Souteiro, médico do CHSJ, pela revisão da linguagem do artigo, à Dr.^a Rita Bettencourt Silva, médica do CHSJ, pela leitura crítica do trabalho ao longo da sua elaboração, e ao colega David Reis, pela ajuda na resolução de algumas questões burocráticas e logísticas.

Anexos

- 1** – Aprovação da Comissão de Ética para a Saúde e Conselho de Administração do Centro Hospitalar São João
- 2** – Normas editoriais da revista “Multiple Sclerosis and Related Disorders”



Exmo. Senhor

Presidente do Conselho de Administração do
Centro Hospitalar de S. João – EPE

Assunto: Pedido de autorização para realização de estudo/projecto de investigação

Nome do Investigador Principal: Beatriz Joana Bettencourt Silva

Título do projecto de investigação: Esclerose Múltipla e Nutrição: Avaliação de doentes com formas progressivas e surto-remissão

Pretendendo realizar no(s) Serviço(s) de Neurologia 
do Centro Hospitalar de S. João – EPE o estudo/projecto de investigação em epígrafe,
solicito a V. Exa., na qualidade de Investigador/Promotor, autorização para a sua
efectivação.

Para o efeito, anexa toda a documentação referida no dossier da Comissão de Ética do
Centro Hospitalar de S. João respeitante a estudos/projectos de investigação, à qual
endereçou pedido de apreciação e parecer.

Com os melhores cumprimentos.

Porto, 5 / Junho / 2015

O INVESTIGADOR/PROMOTOR

Beatriz Bett. Silva

Comissão de Ética para a Saúde – Centro Hospitalar São João / FMUP

Parecer

Título do Projecto Esclerose Múltipla e Nutrição: Avaliação de doentes com formas progressivas e surto-remissão.

Nome do Investigador Principal: Beatriz Joana Bettencourt Silva

Local onde sera realizado o estudo: Serviço de Neurologia, – CHSJ, havendo autorização da respectiva Diretora de Serviço para a realização do mesmo.

Conclusão de Mestrado Integrado em Medicina

Objectivo do estudo:

- Avaliar do ponto de vista nutricional doentes com EM, formas progressivas e surto-remissão, seguidos na Consulta de Doenças Desmielinizantes, do Serviço de Neurologia do Hospital de São João.

Período previsto de conclusão: não definido

Benefício / Risco: N/A

Respeito pela liberdade e autonomia do sujeito do ensaio: Prevê-se a obtenção do consentimento informado, complementado por um suporte de informação escrita para os participantes, que refere os objectivos do estudo, os riscos/benefícios, bem como a liberdade em participar.

Confidencialidade dos dados: está garantida a confidencialidade dos dados e esta informação será restrita aos investigadores.

A Investigadora Principal dispõe de competência técnica e científica para a realização do estudo.

O estudo prevê a realização de questionários, e foram incluídos um exemplar de cada.

Custos: O estudo não prevê custos acrescidos para a instituição.

Parecer: Em face da análise do protocolo de estudo, proponho a sua aprovação pela CES do CHSJ.

Porto, CHSJ, 30 de Junho de 2015

O Relator

A handwritten signature in black ink, appearing to read 'John Preto', with a stylized flourish at the end.

Dr. John Preto

7. SEGURO

- a. *Este estudo/projecto de investigação prevê intervenção clínica que implique a existência de um seguro para os participantes?*

SIM ☐ (Se sim, junte, por favor, cópia da Apólice de Seguro respectiva)

NÃO ☐

NÃO APLICÁVEL ☒

8. TERMO DE RESPONSABILIDADE

Eu, Beatriz Joana Bettencourt Silva,

abaixo-assinado, na qualidade de Investigador Principal, declaro por minha honra que as informações prestadas neste questionário são verdadeiras. Mais declaro que, durante o estudo, serão respeitadas as recomendações constantes da Declaração de Helsínquia (com as emendas de Tóquio 1975, Veneza 1983, Hong-Kong 1989, Somerset West 1996 e Edimburgo 2000) e da Organização Mundial da Saúde, no que se refere à experimentação que envolve seres humanos. Aceito, também, a recomendação da CES de que o recrutamento para este estudo se fará junto de doentes que não tenham participado em outro estudo no decurso do actual internamento ou da mesma consulta.

Porto, 5 / Junho / 2015

Beatriz Bett. Silva


O Investigador Principal

PARECER DA COMISSÃO DE ÉTICA PARA A SAÚDE DO CENTRO HOSPITALAR DE S. JOÃO

emitido na reunião plenária da CES

de
03 / Julho / 2015

A Comissão de Ética para a Saúde
APROVA por unanimidade o parecer do
Relator, pelo que nada tem a opor à
realização deste projecto de investigação.



Prof. Doutor Filipe Almeida
Presidente da Comissão de Ética


[•Your Paper Your Way](#)
[INTRODUCTION](#)
[•Types of article](#)
[•Contact details for submission](#)
[BEFORE YOU BEGIN](#)
[•Ethics in publishing](#)
[•Human and animal rights](#)
[•Conflict of interest](#)
[•Submission declaration and verification](#)
[•Changes to authorship](#)
[•Clinical trial results](#)
[•Reporting clinical trials](#)
[•Registration of clinical trials](#)
[•Copyright](#)
[•Role of the funding source](#)
[•Funding body agreements and policies](#)
[•Open access](#)
[•Green open access](#)
[•Language \(usage and editing services\)](#)
[•Informed consent and patient details](#)
[•Submission](#)
[•Referees](#)
[PREPARATION](#)
[•NEW SUBMISSIONS](#)
[•References](#)
[•Formatting requirements](#)
[•REVISED SUBMISSIONS](#)
[•Article structure](#)
[•Essential title page information](#)
[•Abstract](#)
[•Graphical abstract](#)
[•Highlights](#)
[•Keywords](#)
[•Abbreviations](#)
[•Acknowledgements](#)
[•Math formulae](#)
[•Footnotes](#)
[•Artwork](#)
[•Illustration services](#)
[•Tables](#)
[•References](#)
[•Video data](#)
[•AudioSlides](#)
[•Supplementary material](#)
[•Submission checklist](#)
[AFTER ACCEPTANCE](#)
[•Use of the Digital Object Identifier](#)
[•Online proof correction](#)
[•Offprints](#)
[AUTHOR INQUIRIES](#)

Your Paper Your Way

We now differentiate between the requirements for new and revised submissions. You may choose to submit your manuscript as a single Word or PDF file to be used in the refereeing process. Only when your paper is at the revision stage, will you be requested to put your paper in to a 'correct format' for acceptance and provide the items required for the publication of your article.

To find out more, please visit the [Preparation](#) section below.



Introduction

Types of article

Original Research Articles

Full length research papers will not normally be more than 3500 words in length from the Introduction through the Discussion section and will preferably be shorter. Submission of a paper to Multiple Sclerosis and Related Disorders will be held to imply that it represents original research not previously published (except in the form of an abstract or preliminary report), that it is not being considered for publication elsewhere, and that if accepted by Multiple Sclerosis and Related Disorders it will not be published elsewhere in the same form in any language without the consent of the Publisher. Major papers of topical content will be given priority in publication.

Book Reviews

These are normally submitted by the Book Review Editors, but they welcome suggestions of books for review.

Case Reports

Case reports should detail the clinical, laboratory and neuroimaging features of informative patients. Informative patients should provide insights that inform on genetic contributions to disease, rare clinical manifestations, novel laboratory or imaging features, or highlight important concepts in the differential of MS and related disorders. Case reports should be approximately 1200 words, and should have no more than five key references

Comment

Comments should focus on specific issues relevant to MS and related disorders, or should discuss recent publications. Comments should be less than 800 words and should reference the article(s) upon which the commentary is based.

Clinical Trial papers

Manuscripts detailing the results of clinical trials in MS and related disorders are encouraged. The trial methodology should account for all screened participants, and analyses should observe an intention-to-treat model where appropriate. All sources of funding for the study must be disclosed, and the involvement of the study sponsor must be detailed. Clinical trial manuscripts should be a maximum of 3500 words.

Editorials

The Editors welcome suggestions for editorials which give personal and topical views on subjects within the Journal's area of interest. They should not normally exceed 1500 words in total, including references.

Letters to the Editors

These normally refer to articles previously published in the Journal. The Editors are also willing to consider letters on subjects of direct relevance to the Journal's interest. Letters should not exceed 1000 words in total and, where appropriate, must begin with the reference to the published article about which the author is commenting. Research letters should be submitted as 'letter to the Editors'

Review Articles

Review papers are normally 4000-5000 words in total. Authors are advised to consult one of the Editors with an outline before submitting a review.

Contact details for submission

Authors may send queries concerning the submission process, manuscript status, or journal procedures to the Editorial Office at: MSARD, Editorial Office, ELSEVIER.
E-mail: msard@elsevier.com



Before You Begin

Ethics in publishing

For information on Ethics in publishing and Ethical guidelines for journal publication see <https://www.elsevier.com/publishingethics> and <https://www.elsevier.com/journal-authors/ethics>.

Human and animal rights

If the work involves the use of human subjects, the author should ensure that the work described has been carried out in accordance with The Code of Ethics of the World Medical Association (Declaration of Helsinki) for experiments involving humans, <http://www.wma.net/en/30publications/10policies/b3/index.html>; Uniform Requirements for manuscripts submitted to Biomedical journals, <http://www.icmje.org>. Authors should include a statement in the manuscript that informed consent was obtained for experimentation with human subjects. The privacy rights of human subjects must always be observed.

All animal experiments should be carried out in accordance with the U.K. Animals (Scientific Procedures) Act, 1986 and associated guidelines, [EU Directive 2010/63/EU for animal experiments](http://www.elsevier.com/locate/01675273), or the National Institutes of Health guide for the care and use of Laboratory animals (NIH Publications No. 8023, revised 1978) and the authors should clearly indicate in the manuscript that such guidelines have been followed. **All animal studies need to ensure they comply with the ARRIVE guidelines.** More information can be found at <http://www.nc3rs.org.uk/page.asp?id=1357>.

Checklist for reporting and reviewing studies of experimental animal models of multiple sclerosis and related disorders

The guide, reported here, is intended to act as a checklist to aid both authors and referees of manuscripts, just as the Consolidated Standards of Reporting Trials (CONSORT) guidelines are a compulsory part of reporting clinical trials.

Please click here for the [checklist](#) and the [complete article](#) by Sandra Amor and David Baker.

Conflict of interest

All authors are requested to disclose any actual or potential conflict of interest including any financial, personal or other relationships with other people or organizations within three years of beginning the submitted work that could inappropriately influence, or be perceived to influence, their work. See also <https://www.elsevier.com/conflictsofinterest>. Further information and an example of a Conflict of Interest form can be found at: http://service.elsevier.com/app/answers/detail/a_id/286/supporthub/publishing.

Submission declaration and verification

Submission of an article implies that the work described has not been published previously (except in the form of an abstract or as part of a published lecture or academic thesis or as an electronic preprint, see <https://www.elsevier.com/sharingpolicy>), that it is not under consideration for publication elsewhere, that its publication is approved by all authors and tacitly or explicitly by the responsible authorities where the work was carried out, and that, if accepted, it will not be published elsewhere in the same form, in English or in any other language, including electronically without the written consent of the copyright-holder. To verify originality, your article may be checked by the originality detection service CrossCheck <https://www.elsevier.com/editors/plagdetect>.

Changes to authorship

Authors are expected to consider carefully the list and order of authors **before** submitting their manuscript and provide the definitive list of authors at the time of the original submission. Any addition, deletion or rearrangement of author names in the authorship list should be made only **before** the manuscript has been accepted and only if approved by the journal Editor. To request such a change, the Editor must receive the following from the **corresponding author**: (a) the reason for the change in author list and (b) written confirmation (e-mail, letter) from all authors that they agree with the addition, removal or rearrangement. In the case of addition or removal of authors, this includes confirmation from the author being added or removed.

Only in exceptional circumstances will the Editor consider the addition, deletion or rearrangement of authors **after** the manuscript has been accepted. While the Editor considers the request, publication of the manuscript will be suspended. If the manuscript has already been published in an online issue, any requests approved by the Editor will result in a corrigendum.

Clinical trial results

In line with the position of the International Committee of Medical Journal Editors, the journal will not consider results posted in the same clinical trials registry in which primary registration resides to be prior publication if the results posted are presented in the form of a brief structured (less than 500 words) abstract or table. However, divulging results in other circumstances (e.g., investors' meetings) is discouraged and may jeopardise consideration of the manuscript. Authors should fully disclose all posting in registries of results of the same or closely related work.

Reporting clinical trials

Randomized controlled trials should be presented according to the CONSORT guidelines. At manuscript submission, authors must provide the CONSORT checklist accompanied by a flow diagram that illustrates the progress of patients through the trial, including recruitment, enrollment, randomization, withdrawal and completion, and a detailed description of the randomization procedure. The CONSORT checklist and template flow diagram can be found on <http://www.consort-statement.org>.

Registration of clinical trials

Registration in a public trials registry is a condition for publication of clinical trials in this journal in accordance with International Committee of Medical Journal Editors (ICMJE, <http://www.icmje.org>) recommendations. Trials must register at or before the onset of patient enrolment. The clinical trial registration number should be included at the end of the abstract of the article. A clinical trial is defined as any research study that prospectively assigns human participants or groups of humans to one or more health-related interventions to evaluate the effects of health outcomes. Health-related interventions include any intervention used to modify a biomedical or health-related outcome (for example drugs, surgical procedures, devices, behavioural treatments, dietary interventions, and process-of-care changes). Health outcomes include any biomedical or health-related measures obtained in patients or participants, including pharmacokinetic measures and adverse events. Purely observational studies (those in which the assignment of the medical intervention is not at the discretion of the investigator) will not require registration.

Copyright

Upon acceptance of an article, authors will be asked to complete a 'Journal Publishing Agreement' (for more information on this and copyright, see <https://www.elsevier.com/copyright>). An e-mail will be sent to the corresponding author confirming receipt of the manuscript together with a 'Journal Publishing Agreement' form or a link to the online version of this agreement.

Subscribers may reproduce tables of contents or prepare lists of articles including abstracts for internal circulation within their institutions. Permission of the Publisher is required for resale or distribution outside the institution and for all other derivative works, including compilations and translations (please consult <https://www.elsevier.com/permissions>). If excerpts from other copyrighted works are included, the author(s) must obtain written permission from the copyright owners and credit the source(s) in the article. Elsevier has preprinted forms for use by authors in these cases: please consult <https://www.elsevier.com/permissions>.

For open access articles: Upon acceptance of an article, authors will be asked to complete an 'Exclusive License Agreement' (for more information see <https://www.elsevier.com/OAauthoragreement>). Permitted third party reuse of open access articles is determined by the author's choice of user license (see <https://www.elsevier.com/openaccesslicenses>).

Author rights

As an author you (or your employer or institution) have certain rights to reuse your work. For more information see <https://www.elsevier.com/copyright>.

Role of the funding source

You are requested to identify who provided financial support for the conduct of the research and/or preparation of the article and to briefly describe the role of the sponsor(s), if any, in study design; in the collection, analysis and interpretation of data; in the writing of the report; and in the decision to submit the article for publication. If the funding source(s) had no such involvement then this should be stated.

Funding body agreements and policies

Elsevier has established a number of agreements with funding bodies which allow authors to comply with their funder's open access policies. Some authors may also be reimbursed for associated publication fees. To learn more about existing agreements please visit <https://www.elsevier.com/fundingbodies>.

After acceptance, open access papers will be published under a noncommercial license. For authors requiring a commercial CC BY license, you can apply after your manuscript is accepted for publication.

Open access

This journal offers authors a choice in publishing their research:

Open access

- Articles are freely available to both subscribers and the wider public with permitted reuse
- An open access publication fee is payable by authors or on their behalf e.g. by their research funder or institution

Subscription

- Articles are made available to subscribers as well as developing countries and patient groups through our universal access programs (<https://www.elsevier.com/access>).
- No open access publication fee payable by authors.

Regardless of how you choose to publish your article, the journal will apply the same peer review criteria and acceptance standards.

For open access articles, permitted third party (re)use is defined by the following Creative Commons user licenses:

Creative Commons Attribution-NonCommercial-NoDerivs (CC BY-NC-ND)

For non-commercial purposes, lets others distribute and copy the article, and to include in a collective work (such as an anthology), as long as they credit the author(s) and provided they do not alter or modify the article.

The open access publication fee for this journal is **USD 3000**, excluding taxes. Learn more about Elsevier's pricing policy: <https://www.elsevier.com/openaccesspricing>.

Green open access

Authors can share their research in a variety of different ways and Elsevier has a number of green open access options available. We recommend authors see our green open access page for further information (<http://elsevier.com/greenopenaccess>). Authors can also self-archive their manuscripts immediately and enable public access from their institution's repository after an embargo period. This is the version that has been accepted for publication and which typically includes author-incorporated changes suggested during submission, peer review and in editor-author communications. Embargo period: For subscription articles, an appropriate amount of time is needed for journals to deliver value to subscribing customers before an article becomes freely available to the public. This is the embargo period and it begins from the date the article is formally published online in its final and fully citable form.

This journal has an embargo period of 12 months.

Language (usage and editing services)

Please write your text in good English (American or British usage is accepted, but not a mixture of these). Authors who feel their English language manuscript may require editing to eliminate possible grammatical or spelling errors and to conform to correct scientific English may wish to use the English Language Editing service available from Elsevier's WebShop (<http://webshop.elsevier.com/languageediting/>) or visit our customer support site (<http://support.elsevier.com>) for more information.

Informed consent and patient details

Studies on patients or volunteers require ethics committee approval and informed consent, which should be documented in the paper. Appropriate consents, permissions and releases must be obtained where an author wishes to include case details or other personal information or images of patients and any other individuals in an Elsevier publication. Written consents must be retained by the author and copies of the consents or evidence that such consents have been obtained must be provided to Elsevier on request. For more information, please review the *Elsevier Policy on the Use of Images or Personal Information of Patients or other Individuals*, <https://www.elsevier.com/patient-consent-policy>. Unless you have written permission from the patient (or, where applicable, the next of kin), the personal details of any patient included in any part of the article and in any supplementary materials (including all illustrations and videos) must be removed before submission.

Submission

Our online submission system guides you stepwise through the process of entering your article details and uploading your files. The system converts your article files to a single PDF file used in the peer-review process. Editable files (e.g., Word, LaTeX) are required to typeset your article for final publication. All correspondence, including notification of the Editor's decision and requests for revision, is sent by e-mail.

Submit your article

Please submit your article via  <http://ees.elsevier.com/msard/>

Referees

Please submit the names and institutional e-mail addresses of several potential referees. For more details, visit our [Support site](#). Note that the editor retains the sole right to decide whether or not the suggested reviewers are used.



Preparation

NEW SUBMISSIONS

Submission to this journal proceeds totally online and you will be guided stepwise through the creation and uploading of your files. The system automatically converts your files to a single PDF file, which is used in the peer-review process. As part of the Your Paper Your Way service, you may choose to submit your manuscript as a single file to be used in the refereeing process. This can be a PDF file or a Word document, in any format or lay-out that can be used by referees to evaluate your manuscript. It should contain high enough quality figures for refereeing. If you prefer to do so, you may still provide all or some of the source files at the initial submission. Please note that individual figure files larger than 10 MB must be uploaded separately.

References

There are no strict requirements on reference formatting at submission. References can be in any style or format as long as the style is consistent. Where applicable, author(s) name(s), journal title/book title, chapter title/article title, year of publication, volume number/book chapter and the pagination must be present. Use of DOI is highly encouraged. The reference style used by the journal will be applied to the accepted article by Elsevier at the proof stage. Note that missing data will be highlighted at proof stage for the author to correct.

Formatting requirements

There are no strict formatting requirements but all manuscripts must contain the essential elements needed to convey your manuscript, for example Abstract, Keywords, Introduction, Materials and Methods, Results, Conclusions, Artwork and Tables with Captions. If your article includes any Videos and/or other Supplementary material, this should be included in your initial submission for peer review purposes. Divide the article into clearly defined sections.

Figures and tables embedded in text

Please ensure the figures and the tables included in the single file are placed next to the relevant text in the manuscript, rather than at the bottom or the top of the file.

REVISED SUBMISSIONS

Use of word processing software

Regardless of the file format of the original submission, at revision you must provide us with an editable file of the entire article. Keep the layout of the text as simple as possible. Most formatting codes will be removed and replaced on processing the article. The electronic text should be prepared in a way very similar to that of conventional manuscripts (see also the Guide to Publishing with Elsevier: <https://www.elsevier.com/guidepublication>). See also the section on Electronic artwork. To avoid unnecessary errors you are strongly advised to use the 'spell-check' and 'grammar-check' functions of your word processor.

Article structure

Subdivision - numbered sections

Divide your article into clearly defined and numbered sections. Subsections should be numbered 1.1 (then 1.1.1, 1.1.2, ...), 1.2, etc. (the abstract is not included in section numbering). Use this numbering also for internal cross-referencing: do not just refer to 'the text'. Any subsection may be given a brief heading. Each heading should appear on its own separate line.

Introduction

State the objectives of the work and provide an adequate background, avoiding a detailed literature survey or a summary of the results.

Material and methods

Provide sufficient detail to allow the work to be reproduced. Methods already published should be indicated by a reference: only relevant modifications should be described.

Results

Results should be clear and concise.

Discussion

This should explore the significance of the results of the work, not repeat them. A combined Results and Discussion section is often appropriate. Avoid extensive citations and discussion of published literature.

Conclusions

The main conclusions of the study may be presented in a short Conclusions section, which may stand alone or form a subsection of a Discussion or Results and Discussion section.

Appendices

If there is more than one appendix, they should be identified as A, B, etc. Formulae and equations in appendices should be given separate numbering: Eq. (A.1), Eq. (A.2), etc.; in a subsequent appendix, Eq. (B.1) and so on. Similarly for tables and figures: Table A.1; Fig. A.1, etc.

Essential title page information

- **Title.** Concise and informative. Titles are often used in information-retrieval systems. Avoid abbreviations and formulae where possible.

• **Author names and affiliations.** Please clearly indicate the given name(s) and family name(s) of each author and check that all names are accurately spelled. Present the authors' affiliation addresses (where the actual work was done) below the names. Indicate all affiliations with a lower-case superscript letter immediately after the author's name and in front of the appropriate address. Provide the full postal address of each affiliation, including the country name and, if available, the e-mail address of each author.

• **Corresponding author.** Clearly indicate who will handle correspondence at all stages of refereeing and publication, also post-publication. **Ensure that the e-mail address is given and that contact details are kept up to date by the corresponding author.**

• **Present/permanent address.** If an author has moved since the work described in the article was done, or was visiting at the time, a 'Present address' (or 'Permanent address') may be indicated as a footnote to that author's name. The address at which the author actually did the work must be retained as the main, affiliation address. Superscript Arabic numerals are used for such footnotes.

Abstract

A concise and factual abstract is required. The abstract should state briefly the purpose of the research, the principal results and major conclusions. An abstract is often presented separately from the article, so it must be able to stand alone. For this reason, References should be avoided, but if essential, then cite the author(s) and year(s). Also, non-standard or uncommon abbreviations should be avoided, but if essential they must be defined at their first mention in the abstract itself.

Graphical abstract

Although a graphical abstract is optional, its use is encouraged as it draws more attention to the online article. The graphical abstract should summarize the contents of the article in a concise, pictorial form designed to capture the attention of a wide readership. Graphical abstracts should be submitted as a separate file in the online submission system. Image size: Please provide an image with a minimum of 531 × 1328 pixels (h × w) or proportionally more. The image should be readable at a size of 5 × 13 cm using a regular screen resolution of 96 dpi. Preferred file types: TIFF, EPS, PDF or MS Office files. See  <https://www.elsevier.com/graphicalabstracts> for examples.

Authors can make use of Elsevier's Illustration and Enhancement service to ensure the best presentation of their images and in accordance with all technical requirements: [Illustration Service](#).

Highlights

Highlights are mandatory for this journal. They consist of a short collection of bullet points that convey the core findings of the article and should be submitted in a separate editable file in the online submission system. Please use 'Highlights' in the file name and include 3 to 5 bullet points (maximum 85 characters, including spaces, per bullet point). See  <https://www.elsevier.com/highlights> for examples.

Keywords

Immediately after the abstract, provide a maximum of 6 keywords, using American spelling and avoiding general and plural terms and multiple concepts (avoid, for example, 'and', 'of'). Be sparing with abbreviations: only abbreviations firmly established in the field may be eligible. These keywords will be used for indexing purposes.

Abbreviations

Define abbreviations that are not standard in this field in a footnote to be placed on the first page of the article. Such abbreviations that are unavoidable in the abstract must be defined at their first mention there, as well as in the footnote. Ensure consistency of abbreviations throughout the article.

Acknowledgements

Collate acknowledgements in a separate section at the end of the article before the references and do not, therefore, include them on the title page, as a footnote to the title or otherwise. List here those individuals who provided help during the research (e.g., providing language help, writing assistance or proof reading the article, etc.).

Math formulae

Please submit math equations as editable text and not as images. Present simple formulae in line with normal text where possible and use the solidus (/) instead of a horizontal line for small fractional terms, e.g., X/Y. In principle, variables are to be presented in italics. Powers of e are often more conveniently denoted by exp. Number consecutively any equations that have to be displayed separately from the text (if referred to explicitly in the text).

Footnotes

Footnotes should be used sparingly. Number them consecutively throughout the article. Many word processors build footnotes into the text, and this feature may be used. Should this not be the case, indicate the position of footnotes in the text and present the footnotes themselves separately at the end of the article.

Artwork

Electronic artwork

General points

- Make sure you use uniform lettering and sizing of your original artwork.
- Preferred fonts: Arial (or Helvetica), Times New Roman (or Times), Symbol, Courier.
- Number the illustrations according to their sequence in the text.
- Use a logical naming convention for your artwork files.
- Indicate per figure if it is a single, 1.5 or 2-column fitting image.
- For Word submissions only, you may still provide figures and their captions, and tables within a single file at the revision stage.
- Please note that individual figure files larger than 10 MB must be provided in separate source files.

A detailed guide on electronic artwork is available on our website:

 <https://www.elsevier.com/artworkinstructions>.

You are urged to visit this site; some excerpts from the detailed information are given here.

Formats

Regardless of the application used, when your electronic artwork is finalized, please 'save as' or convert the images to one of the following formats (note the resolution requirements for line drawings, halftones, and line/halftone combinations given below):

- EPS (or PDF): Vector drawings. Embed the font or save the text as 'graphics'.
- TIFF (or JPG): Color or grayscale photographs (halftones): always use a minimum of 300 dpi.
- TIFF (or JPG): Bitmapped line drawings: use a minimum of 1000 dpi.
- TIFF (or JPG): Combinations bitmapped line/half-tone (color or grayscale): a minimum of 500 dpi is required.

Please do not:

- Supply files that are optimized for screen use (e.g., GIF, BMP, PICT, WPG); the resolution is too low.
- Supply files that are too low in resolution.
- Submit graphics that are disproportionately large for the content.

Color artwork

Please make sure that artwork files are in an acceptable format (TIFF (or JPEG), EPS (or PDF), or MS Office files) and with the correct resolution. If, together with your accepted article, you submit usable color figures then Elsevier will ensure, at no additional charge,

that these figures will appear in color online (e.g., ScienceDirect and other sites) regardless of whether or not these illustrations are reproduced in color in the printed version. **For color reproduction in print, you will receive information regarding the costs from Elsevier after receipt of your accepted article.** Please indicate your preference for color: in print or online only. For further information on the preparation of electronic artwork, please see <https://www.elsevier.com/artworkinstructions>.

Illustration services

Elsevier's WebShop (<http://webshop.elsevier.com/illustrationservices>) offers Illustration Services to authors preparing to submit a manuscript but concerned about the quality of the images accompanying their article. Elsevier's expert illustrators can produce scientific, technical and medical-style images, as well as a full range of charts, tables and graphs. Image 'polishing' is also available, where our illustrators take your image(s) and improve them to a professional standard. Please visit the website to find out more.

Figure captions

Ensure that each illustration has a caption. A caption should comprise a brief title (**not** on the figure itself) and a description of the illustration. Keep text in the illustrations themselves to a minimum but explain all symbols and abbreviations used.

Tables

Please submit tables as editable text and not as images. Tables can be placed either next to the relevant text in the article, or on separate page(s) at the end. Number tables consecutively in accordance with their appearance in the text and place any table notes below the table body. Be sparing in the use of tables and ensure that the data presented in them do not duplicate results described elsewhere in the article. Please avoid using vertical rules.

References

Citation in text

Please ensure that every reference cited in the text is also present in the reference list (and vice versa). Any references cited in the abstract must be given in full. Unpublished results and personal communications are not recommended in the reference list, but may be mentioned in the text. If these references are included in the reference list they should follow the standard reference style of the journal and should include a substitution of the publication date with either 'Unpublished results' or 'Personal communication'. Citation of a reference as 'in press' implies that the item has been accepted for publication.

Reference management software

This journal has standard templates available in key reference management packages EndNote (<http://www.endnote.com/support/enstyles.asp>) and Reference Manager (<http://refman.com/support/rmstyles.asp>). Using plug-ins to wordprocessing packages, authors only need to select the appropriate journal template when preparing their article and the list of references and citations to these will be formatted according to the journal style which is described below.

Reference links

Increased discoverability of research and high quality peer review are ensured by online links to the sources cited. In order to allow us to create links to abstracting and indexing services, such as Scopus, CrossRef and PubMed, please ensure that data provided in the references are correct. Please note that incorrect surnames, journal/book titles, publication year and pagination may prevent link creation. When copying references, please be careful as they may already contain errors. Use of the DOI is encouraged.

Web references

As a minimum, the full URL should be given and the date when the reference was last accessed. Any further information, if known (DOI, author names, dates, reference to a source publication, etc.), should also be given. Web references can be listed separately (e.g., after the reference list) under a different heading if desired, or can be included in the reference list.

References in a special issue

Please ensure that the words 'this issue' are added to any references in the list (and any citations in the text) to other articles in the same Special Issue.

Reference management software

Most Elsevier journals have their reference template available in many of the most popular reference management software products. These include all products that support Citation Style Language styles (<http://citationstyles.org>), such as Mendeley (<http://www.mendeley.com/features/reference-manager>) and Zotero (<https://www.zotero.org/>), as well as EndNote (<http://endnote.com/downloads/styles>). Using the word processor plug-ins from these products, authors only need to select the appropriate journal template when preparing their article, after which citations and bibliographies will be automatically formatted in the journal's style. If no template is yet available for this journal, please follow the format of the sample references and citations as shown in this Guide.

Users of Mendeley Desktop can easily install the reference style for this journal by clicking the following link:

<http://open.mendeley.com/use-citation-style/multiple-sclerosis-and-related-disorders>

When preparing your manuscript, you will then be able to select this style using the Mendeley plug-ins for Microsoft Word or LibreOffice.

Reference formatting

There are no strict requirements on reference formatting at submission. References can be in any style or format as long as the style is consistent. Where applicable, author(s) name(s), journal title/book title, chapter title/article title, year of publication, volume number/book chapter and the pagination must be present. Use of DOI is highly encouraged. The reference style used by the journal will be applied to the accepted article by Elsevier at the proof stage. Note that missing data will be highlighted at proof stage for the author to correct. If you do wish to format the references yourself they should be arranged according to the following examples:

Reference style

Text: All citations in the text should refer to:

1. *Single author:* the author's name (without initials, unless there is ambiguity) and the year of publication;
 2. *Two authors:* both authors' names and the year of publication;
 3. *Three or more authors:* first author's name followed by 'et al.' and the year of publication.
- Citations may be made directly (or parenthetically). Groups of references should be listed first alphabetically, then chronologically. Examples: 'as demonstrated (Allan, 2000a, 2000b, 1999; Allan and Jones, 1999). Kramer et al. (2010) have recently shown ...'

List: References should be arranged first alphabetically and then further sorted chronologically if necessary. More than one reference from the same author(s) in the same year must be identified by the letters 'a', 'b', 'c', etc., placed after the year of publication.

Examples:

Reference to a journal publication:

Van der Geer, J., Hanraads, J.A.J., Lupton, R.A., 2010. The art of writing a scientific article. J. Sci. Commun. 163, 51–59.

Reference to a book:

Strunk Jr., W., White, E.B., 2000. The Elements of Style, fourth ed. Longman, New York.

Reference to a chapter in an edited book:

Mettam, G.R., Adams, L.B., 2009. How to prepare an electronic version of your article, in: Jones, B.S., Smith, R.Z. (Eds.), Introduction to the Electronic Age. E-Publishing Inc., New York, pp. 281–304.

Reference to a website:

Cancer Research UK, 1975. Cancer statistics reports for the UK.

<http://www.cancerresearchuk.org/aboutcancer/statistics/cancerstatsreport/> (accessed 13.03.03).

Journal abbreviations source

Journal names should be abbreviated according to the List of Title Word Abbreviations: <http://www.issn.org/services/online-services/access-to-the-ltwa/>.

Video data

Elsevier accepts video material and animation sequences to support and enhance your scientific research. Authors who have video or animation files that they wish to submit with their article are strongly encouraged to include links to these within the body of the article. This can be done in the same way as a figure or table by referring to the video or animation content and noting in the body text where it should be placed. All submitted files should be properly labeled so that they directly relate to the video file's content. In order to ensure that your video or animation material is directly usable, please provide the files in one of our recommended file formats with a preferred maximum size of 150 MB. Video and animation files supplied will be published online in the electronic version of your article in Elsevier Web products, including ScienceDirect: <http://www.sciencedirect.com>. Please supply 'stills' with your files: you can choose any frame from the video or animation or make a separate image. These will be used instead of standard icons and will personalize the link to your video data. For more detailed instructions please visit our video instruction pages at <https://www.elsevier.com/artworkinstructions>. Note: since video and animation cannot be embedded in the print version of the journal, please provide text for both the electronic and the print version for the portions of the article that refer to this content.

Patient Details

Every video submission must consist of high-resolution images and a consent [form](#) for publication for educational purposes signed by the patient see form, please see the **Patient Details** section below. The Editors reserve the right to ask for additional video/s or video modifications.

Patient Details Studies on patients or volunteers require ethics committee approval and informed consent, which should be documented in your paper.

If you wish to include images of patients or case details in an Elsevier publication, you will need to adhere to the following requirements:

In order to comply with data protection and privacy rules, each individual who appears in any video, recording, photograph or case report must be made aware in advance of the fact that such photographs are being taken or such video, recording or report is being made and of all of the purposes for which you wish to use them and that individual (or next of kin in the case of children) must give his/her explicit written consent. If such consent is made subject to any conditions (for example, adopting measures to prevent personal identification of the person concerned), Elsevier must be made aware of all such conditions. Written consents must be provided to Elsevier on request.

The author is responsible for obtaining all necessary consents from patients for (i) the performance of any medical procedure involved, as well as (ii) a release permitting our use of the relevant material. It is our insurers' preference that we do not have any direct contractual relationship with the patients themselves. Please download the Patient consent form [here](#)

AudioSlides

The journal encourages authors to create an AudioSlides presentation with their published article. AudioSlides are brief, webinar-style presentations that are shown next to the online article on ScienceDirect. This gives authors the opportunity to summarize their research in their own words and to help readers understand what the paper is about. More information and examples are available at <https://www.elsevier.com/audioslides>. Authors of this journal will automatically receive an invitation e-mail to create an AudioSlides presentation after acceptance of their paper.

Supplementary material

Supplementary material can support and enhance your scientific research. Supplementary files offer the author additional possibilities to publish supporting applications, high-resolution images, background datasets, sound clips and more. Please note that such items are published online exactly as they are submitted; there is no typesetting involved (supplementary data supplied as an Excel file or as a PowerPoint slide will appear as such online). Please submit the material together with the article and supply a concise and descriptive caption for each file. If you wish to make any changes to supplementary data during any stage of the process, then please make sure to provide an updated file, and do not annotate any corrections on a previous version. Please also make sure to switch off the 'Track Changes' option in any Microsoft Office files as these will appear in the published supplementary file(s). For more detailed instructions please visit our artwork instruction pages at <https://www.elsevier.com/artworkinstructions>.

Submission checklist

The following list will be useful during the final checking of an article prior to sending it to the journal for review. Please consult this Guide for Authors for further details of any item.

Ensure that the following items are present:

One author has been designated as the corresponding author with contact details:

- E-mail address
- Full postal address

All necessary files have been uploaded, and contain:

- Keywords
- All figure captions
- All tables (including title, description, footnotes)

Further considerations

- Manuscript has been 'spell-checked' and 'grammar-checked'
- All references mentioned in the Reference list are cited in the text, and vice versa
- Permission has been obtained for use of copyrighted material from other sources (including the Internet)
- Printed version of figures (if applicable) in color or black-and-white
- Indicate clearly whether or not color or black-and-white in print is required.

For any further information please visit our customer support site at <http://support.elsevier.com>.



After Acceptance

Availability of accepted article

This journal makes articles available online as soon as possible after acceptance. This concerns the accepted article (both in HTML and PDF format), which has not yet been copyedited, typeset or proofread. A Digital Object Identifier (DOI) is allocated, thereby making it fully citable and searchable by title, author name(s) and the full text. The article's PDF also carries a disclaimer stating that it is an unedited article. Subsequent production stages will simply replace this version.

Use of the Digital Object Identifier

The Digital Object Identifier (DOI) may be used to cite and link to electronic documents. The DOI consists of a unique alpha-numeric character string which is assigned to a document by the publisher upon the initial electronic publication. The assigned DOI never changes. Therefore, it is an ideal medium for citing a document, particularly 'Articles in press' because they have not yet received their full bibliographic information. Example of a correctly given DOI (in URL format; here an article in the journal *Physics Letters B*):

 <http://dx.doi.org/10.1016/j.physletb.2010.09.059>

When you use a DOI to create links to documents on the web, the DOIs are guaranteed never to change.

Online proof correction

Corresponding authors will receive an e-mail with a link to our online proofing system, allowing annotation and correction of proofs online. The environment is similar to MS Word: in addition to editing text, you can also comment on figures/tables and answer questions from the Copy Editor. Web-based proofing provides a faster and less error-prone process by allowing you to directly type your corrections, eliminating the potential introduction of errors.

If preferred, you can still choose to annotate and upload your edits on the PDF version. All instructions for proofing will be given in the e-mail we send to authors, including alternative methods to the online version and PDF.

We will do everything possible to get your article published quickly and accurately. Please use this proof only for checking the typesetting, editing, completeness and correctness of the text, tables and figures. Significant changes to the article as accepted for publication will only be considered at this stage with permission from the Editor. It is important to ensure that all corrections are sent back to us in one communication. Please check carefully before replying, as inclusion of any subsequent corrections cannot be guaranteed. Proofreading is solely your responsibility.

Offprints

The corresponding author, at no cost, will be provided with a personalized link providing 50 days free access to the final published version of the article on [ScienceDirect](#). This link can also be used for sharing via email and social networks. For an extra charge, paper offprints can be ordered via the offprint order form which is sent once the article is accepted for publication. Both corresponding and co-authors may order offprints at any time via Elsevier's WebShop ( <http://webshop.elsevier.com/myarticleservices/offprints>). Authors requiring printed copies of multiple articles may use Elsevier WebShop's 'Create Your Own Book' service to collate multiple articles within a single cover ( <http://webshop.elsevier.com/myarticleservices/booklets>).



Author Inquiries

You can track your submitted article at  <https://www.elsevier.com/track-submission>. You can track your accepted article at  <https://www.elsevier.com/trackarticle>. You are also welcome to contact Customer Support via  <http://support.elsevier.com>.

Copyright © 2016 [Elsevier](#) Inc. All rights reserved. | [Privacy Policy](#) | [Terms & Conditions](#) | [About Us](#) | [Help & Contact](#)
The content on this site is intended for health professionals.

Advertisements on this site do not constitute a guarantee or endorsement by the journal, Association, or publisher of the quality or value of such product or of the claims made for it by its manufacturer.